18F-FDOPA PET and MRI characteristics correlate with degree of malignancy and predict survival in treatment-naïve gliomas: a cross-sectional study

A surgical strategy using a fusion image constructed from 11C-methionine PET, 18F-FDG-PET and MRI for glioma with no or minimum contrast enhancement

(2018) Makoto Ideguchi et al.   JOURNAL OF NEURO-ONCOLOGY

IDH mutation is paradoxically associated with higher 18F-FDOPA PET uptake in diffuse grade II and grade III gliomas

(2017) A. Verger et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma

(2017) Roger Stupp et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Evidence and context of use for contrast enhancement as a surrogate of disease burden and treatment response in malignant glioma

(2017) Benjamin M Ellingson et al.   NEURO-ONCOLOGY

Baseline pretreatment contrast enhancing tumor volume including central necrosis is a prognostic factor in recurrent glioblastoma: evidence from single and multicenter trials

(2016) Benjamin M. Ellingson et al.   NEURO-ONCOLOGY

Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas

(2016) Nathalie L. Albert et al.   NEURO-ONCOLOGY

Upfront bevacizumab may extend survival for glioblastoma patients who do not receive second-line therapy: an exploratory analysis of AVAglio

(2016) Olivier L. Chinot et al.   NEURO-ONCOLOGY

Correlation of SUV-Derived Indices With Tumoral Aggressiveness of Gliomas in Static 18F-FDOPA PET

(2015) Lucile Janvier et al.   CLINICAL NUCLEAR MEDICINE

Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma

(2015) Roger Stupp et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Incidence and prognostic significance of non-enhancing cortical signal abnormality in glioblastoma

(2015) Arian Lasocki et al.   Journal of Medical Imaging and Radiation Oncology

CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2008-2012

(2015) Quinn T. Ostrom et al.   NEURO-ONCOLOGY

Increasing feasibility and utility of 18 F-FDOPA PET for the management of glioma

(2015) Christopher Bell et al.   NUCLEAR MEDICINE AND BIOLOGY

Comparison of the Amino Acid Tracers 18F-FET and 18F-DOPA in High-Grade Glioma Patients

(2014) C. Lapa et al.   JOURNAL OF NUCLEAR MEDICINE

Evaluation of Quantitative Criteria for Glioma Grading With Static and Dynamic 18F-FDopa PET/CT

(2013) Christophe Nioche et al.   CLINICAL NUCLEAR MEDICINE

Increased sensitivity to radiochemotherapy in IDH1 mutant glioblastoma as demonstrated by serial quantitative MR volumetry

(2013) A. N. Tran et al.   NEURO-ONCOLOGY

Biopsy validation of 18F-DOPA PET and biodistribution in gliomas for neurosurgical planning and radiotherapy target delineation: results of a prospective pilot study

(2013) D. H. Pafundi et al.   NEURO-ONCOLOGY

Recurrent Glioblastoma Treated with Bevacizumab: Contrast-enhanced T1-weighted Subtraction Maps Improve Tumor Delineation and Aid Prediction of Survival in a Multicenter Clinical Trial

(2013) Benjamin M. Ellingson et al.   RADIOLOGY

Diagnostic Accuracy of PET for Recurrent Glioma Diagnosis: A Meta-Analysis

(2012) T. Nihashi et al.   AMERICAN JOURNAL OF NEURORADIOLOGY

Correlation of MRI-Derived Apparent Diffusion Coefficients in Newly Diagnosed Gliomas with [18F]-Fluoro-L-Dopa PET: What Are We Really Measuring with Minimum ADC?

(2012) S. Rose et al.   AMERICAN JOURNAL OF NEURORADIOLOGY

The role of LAT1 in 18F-DOPA uptake in malignant gliomas

(2012) Ryan S. Youland et al.   JOURNAL OF NEURO-ONCOLOGY

Impact of 3,4-Dihydroxy-6-18F-Fluoro-L-Phenylalanine PET/CT on Managing Patients with Brain Tumors: The Referring Physician's Perspective

(2012) F. Walter et al.   JOURNAL OF NUCLEAR MEDICINE

11C-Methionine PET for Grading and Prognostication in Gliomas: A Comparison Study with 18F-FDG PET and Contrast Enhancement on MRI

(2012) T. Singhal et al.   JOURNAL OF NUCLEAR MEDICINE

Diagnostic Performance of 18F-FET PET in Newly Diagnosed Cerebral Lesions Suggestive of Glioma

(2012) M. Rapp et al.   JOURNAL OF NUCLEAR MEDICINE

Performance of 18F-Fluoro-Ethyl-Tyrosine (18F-FET) PET for the Differential Diagnosis of Primary Brain Tumor: A Systematic Review and Metaanalysis

(2012) V. Dunet et al.   JOURNAL OF NUCLEAR MEDICINE

Canine Lat1: Molecular Structure, Distribution and Its Expression in Cancer Samples

(2012) Hideharu OCHIAI et al.   JOURNAL OF VETERINARY MEDICAL SCIENCE

Dynamic O-(2-[18F]fluoroethyl)-L-tyrosine (F-18 FET) PET for Glioma Grading

(2011) Maria Lucia Calcagni et al.   CLINICAL NUCLEAR MEDICINE

Correlation of 6-18F-Fluoro-L-Dopa PET Uptake with Proliferation and Tumor Grade in Newly Diagnosed and Recurrent Gliomas

(2010) B. J. Fueger et al.   JOURNAL OF NUCLEAR MEDICINE

Comparative Evaluation of F-18 FDOPA, F-18 FDG, and F-18 FLT-PET/CT for Metabolic Imaging of Low Grade Gliomas

(2009) Madhavi Tripathi et al.   CLINICAL NUCLEAR MEDICINE

Methyl-L-11C-Methionine PET as a Diagnostic Marker for Malignant Progression in Patients with Glioma

(2009) R. T. Ullrich et al.   JOURNAL OF NUCLEAR MEDICINE

18F-FDOPA PET/MRI fusion in patients with primary/recurrent gliomas: Initial experience

(2008) Carlos J. Ledezma et al.   EUROPEAN JOURNAL OF RADIOLOGY